Firefly Bio
Signal active
Organization
Contact Information
Overview
Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
About
Industries
Biotechnology, Medical
Founded
2022
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Firefly Bio headquartered in United States, North America, operates in the Biotechnology, Medical sector. The company focuses on Biotechnology and has secured $752.0M in funding across 8 round(s). With a team of 11-50 employees, Firefly Bio is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Firefly Bio, raised $94.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
1
Investors
4
Lead Investors
0
Total Funding Amount
$94.0M
Details
1
Firefly Bio has raised a total of $94.0M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2024 | Early Stage Venture | 94.0M |
Investors
Firefly Bio is funded by 8 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Versant Ventures | - | FUNDING ROUND - Versant Ventures | 94.0M |
| Todd Foley | - | FUNDING ROUND - Todd Foley | 94.0M |
| Firefly Bio | - | FUNDING ROUND - Firefly Bio | 94.0M |
| MPM Capital | - | FUNDING ROUND - MPM Capital | 94.0M |
Recent Activity
There is no recent news or activity for this profile.